Clinical Trial Update: Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Pfizer's PD-1 inhibitor sasanlimab (PF-06801591) is being studied in Phase 1/2 in adults with advanced cancers, including non-small-cell lung cancer, with trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Sasanlimab (sasanlimab)

Snippet

Sponsor: Pfizer | Conditions: Advanced Malignancies, Non-small-cell Lung Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-05-08